Skip to content
Clinical Trials – home
SlovakiaBack to Slovakia

Clinical trials in Nove Mesto Nad Vahom – page 18

246 clinical trials in Nove Mesto Nad Vahom, Slovakia. Every trial is listed in the EU Clinical Trials Register and updated daily.

SlovakiaOur site in SlovakiaKlinickeSkusky.sk(opens in a new tab)
Nove Mesto Nad Vahom at a glance
246
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

246 trials in Nove Mesto Nad Vahom

Open in trial search

Study on AVP-786 for Treating Agitation in Alzheimer's Dementia Patients

Investigational
Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Substances:Quinidine Sulfate
  • Sponsor:Otsuka Pharmaceutical Development & Commercialization Inc.

Study on the Long-term Safety of Cenobamate for Patients with Primary Generalized Tonic-Clonic Seizures

Investigational
Countries:SlovakiaSlovakia
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Cenobamate
  • Sponsor:Sk Life Science Inc.

Study of Secukinumab for Maintaining Remission in Patients with Non-Radiographic Axial Spondyloarthritis

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Secukinumab
  • Sponsor:Novartis Pharma AG

Study on Tiragolumab and Atezolizumab for Patients with Resected Stage IIB-IIIB Non-Small Cell Lung Cancer After Chemotherapy

Registered drug
Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Sponsor:F. Hoffmann-La Roche AG

Petit mal epilepsy+1

Not recruiting

Study of brivaracetam as a treatment for childhood and juvenile absence epilepsy in patients aged 2-25 years

Registered drug
Countries:SlovakiaSlovakia
  • Participants:0–17 years · 18–64 years
  • Substances:Brivaracetam
  • Sponsor:UCB Biopharma

Study of BP05 and Ranibizumab Efficacy and Safety in Patients with Wet Age-Related Macular Degeneration

Registered drugNo placebo
Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Substances:Ranibizumab
  • Sponsor:Curateq Biologics Private Limited

Hidradenitis

Not recruiting

Study on Long-Term Use of Spesolimab for Patients with Hidradenitis Suppurativa Who Completed a Previous Spesolimab Study

Investigational
Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Substances:Spesolimab
  • Sponsor:Boehringer Ingelheim Espana S.A.

Study of Encorafenib, Binimetinib, and Pembrolizumab for Patients with BRAF V600E/K Mutation-Positive Melanoma After Anti-PD-1 Therapy

Registered drugNo placebo
Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Substances:Binimetinib
  • Sponsor:Pfizer Inc.

Study of talazoparib and enzalutamide combination in men with DDR gene mutated metastatic castration-sensitive prostate cancer

Registered drug
Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Substances:Enzalutamide
  • Sponsor:Pfizer Inc.

Cardiac failure

Not recruiting

Study on Balcinrenone and Dapagliflozin for Patients with Heart Failure and Kidney Problems

Registered drug
Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Substances:Balcinrenone
  • Sponsor:AstraZeneca AB

Osteoarthritis

Not recruiting

Study on the Effects of DFV890 for Pain Relief in Patients with Knee Osteoarthritis

Registered drug
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:DFV890
  • Sponsor:Novartis Pharma AG

Study on the Effectiveness and Safety of Remibrutinib Compared to Teriflunomide for Patients with Relapsing Multiple Sclerosis

Registered drug
Countries:SlovakiaSlovakia
  • Participants:18–64 years
  • Substances:Charcoal, Activated
  • Sponsor:Novartis Pharma AG

Other cities in Slovakia

The busiest research cities in the country

All 88 cities in Slovakia

Clinical research in Nove Mesto Nad Vahom

What the registry says about research in the country

01 Cardiovascular Diseases

Clinical trial activity in Stara Tura is focused on cardiovascular diseases, with studies involving adults who have atherosclerotic cardiovascular disease and chronic kidney disease. The research is aimed at better understanding how new treatments may lower the risk of serious heart-related events.

  • Testing new approaches for atherosclerotic cardiovascular disease and chronic kidney disease
  • Studying established cardiovascular disease and high cardiovascular risk
  • Evaluating treatment options for hypertension

These trials are designed to assess whether new therapies can improve prevention of major cardiovascular complications and support better long-term outcomes.

02 Cardiometabolic and Kidney-Related Risk

The local research portfolio also addresses overlapping cardiovascular and kidney-related risk, reflecting the close connection between blood vessel disease, blood pressure control, and renal health. This work helps evaluate whether emerging treatments can reduce events such as heart attack, stroke, or heart failure.

  • Improving outcomes in people with high cardiovascular risk
  • Exploring prevention strategies for heart failure and related complications
  • Supporting better control of hypertension in high-risk patients

In this setting, researchers are focusing on whether new therapies can offer stronger protection than standard care for patients most vulnerable to major cardiovascular events.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.